Overview
Lovaza and Vascepa are types of omega 3 fatty acids indicated as adjuncts to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa is also indicated as an adjunct to statin therapy to reduce the risk of myocardial infarction, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglycerides.

Coverage Guidelines
Approval will be granted if the member meets the following drug specific criteria:

**Omega-3 acid ethyl esters (Lovaza®):**
1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) AND
2. Patient is new to AllWays Health Partners and has been stabilized on omega-3-acid ethyl esters (Lovaza®) AND
3. The member will maintain a lipid-lowering diet and exercise regimen during treatment
OR
1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) AND
2. The member has had a documented side effect, allergy, or treatment failure with a minimum of one agent from each of the following categories:
   a. Fibric acid derivatives (e.g. fenofibrate, gemfibrozil, etc.)
   b. Long-acting niacin agents (e.g. niacin ER, Niaspan®, etc.)
   c. HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin, rosuvastatin, etc.)
   AND
3. The member will maintain a lipid-lowering diet and exercise regimen during treatment
**Vascepa® (icosapent ethyl):**

1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) **AND**
2. The member is new to AllWays Health Partners and has been stabilized on omega-3-acid ethyl esters (Vascepa®) **AND**
3. The member will maintain a lipid-lowering diet and exercise regimen during treatment **OR**
1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) **AND**
2. The member has had a documented side effect, allergy, or treatment failure with a minimum of one agent from each of the following categories:
   a. Fibric acid derivatives (e.g. fenofibrate, gemfibrozil, etc.)
   b. Long-acting niacin agents (e.g. niacin ER, Niaspan®, etc.)
   c. HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin, rosuvastatin, etc.) **AND**
3. The member has had a documented side effect, allergy, or treatment failure with omega-3-acid ethyl esters (Lovaza®) **AND**
4. The member will maintain a lipid-lowering diet and exercise regimen during treatment

**Limitations**

Approvals will be granted for a duration of 3 years (36 months)

**References**

1. Omega-3 fatty acids [prescribing information]. Tempe, AZ: Century HealthCare Inc; received July 2018
2. Lovaza (omega-3-acid ethyl esters) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2015.

**Review History**

2013: Implemented
11/2016: Reviewed P&T
11/20/2017: Updated P&T
11/26/2018: Reviewed P&T

**Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.